US OptionsDetailed Quotes
MRNA250404C41000
- 0.01
- 0.000.00%
15min DelayClose Apr 4 16:00 ET
0.00High0.00Low
0.00Open0.01Pre Close0 Volume244 Open Interest41.00Strike Price0.00Turnover7294.16%IV62.80%PremiumApr 4, 2025Expiry Date0.00Intrinsic Value100Multiplier-11DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type0.0068Delta0.0040Gamma2519.00Leverage Ratio-15.7616Theta0.0000Rho17.08Eff Leverage0.0000Vega
Moderna Stock Discussion
Sign in to post a comment
2
1
$Moderna (MRNA.US)$ ppl see moderna through COVID and resent RFK bs statements. The true value of moderna which is in a sense quite unmeasurable is that the company was able to produce a mRNA vaccine on industrial scale and this was done with success. The sky is the limit in this technology unless it is a rubbish mistake which obviously it isn't. even in case the long lasting side effects would be potentially really harmful - say it to a patient with cancer receiving individual treatment based on...
2
2
$Moderna (MRNA.US)$this trash is back to 2020 price and below. just wipe out![]()
$Moderna (MRNA.US)$
Moderna Reveals Breakthrough Data on JN.1 Vaccine and 5 More Disease Programs
Moderna Reveals Breakthrough Data on JN.1 Vaccine and 5 More Disease Programs
1
$Moderna (MRNA.US)$decided to cut lost at average 39.7...too damn disappointed.
2
1
$Foghorn Therapeutics (FHTX.US)$ $Moderna (MRNA.US)$ $Sana Biotechnology (SANA.US)$
Major Breakthrough: Pfizer Teams With Flagship to Develop AI-Driven Autoimmune Treatments
Major Breakthrough: Pfizer Teams With Flagship to Develop AI-Driven Autoimmune Treatments
1
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Morning Movers
Gapping Up
$Corcept Therapeutics (CORT.US)$ surged over 60% after the company announced that its Phase 3 trial, ROSELLA, met its primary endpoint, improving progression-free survival in platinum-resistant ovarian cancer patients.
$QuantaSing Group (QSG.US)$ surged 20.18% in pre-market trading following a 12% increase on Friday. Last week, QuantaSing Group expanded into the pop toys market through the strategic acqui...
Gapping Up
$Corcept Therapeutics (CORT.US)$ surged over 60% after the company announced that its Phase 3 trial, ROSELLA, met its primary endpoint, improving progression-free survival in platinum-resistant ovarian cancer patients.
$QuantaSing Group (QSG.US)$ surged 20.18% in pre-market trading following a 12% increase on Friday. Last week, QuantaSing Group expanded into the pop toys market through the strategic acqui...
19
10
1
1
No comment yet
Ironman Latest Mark : can bank be resilienced stock ?